For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service free of charge at certain sites in the UK.
Here you can find out more about BRCA testing, what the AstraZeneca
Tumour BRCA testing service
AstraZeneca are offering a tumour BRCA testing service free of charge at specified collaboration laboratories for patients who meet the eligibility criteria. This is to ensure patients who have a somatic BRCAm are identified and are given the opportunity to access treatments such as Lynparza.
The testing process is straightforward and can be completed in several simple steps.